Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Phase 2 Completed
17 enrolled 11 charts
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Phase 1 Completed
9 enrolled 10 charts
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase 1/2 Completed
87 enrolled 24 charts
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Phase 1 Completed
2 enrolled
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Phase 1 Completed
3 enrolled
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Phase 2 Completed
43 enrolled 9 charts
Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer
Phase 1 Completed
10 enrolled
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Phase 1/2 Completed
5 enrolled
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Phase 1 Completed
19 enrolled
CD30 CAR for CD30+ NSGCT
Phase 2 Completed
2 enrolled
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Phase NA Completed
13 enrolled 10 charts
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Phase 3 Completed
1,023 enrolled
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Phase 2 Completed
78 enrolled 13 charts
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Phase 2 Completed
40 enrolled 17 charts
ICLL07GAI
Phase 2 Completed
135 enrolled
Epigenetic Reprogramming in Relapse/Refractory AML
Phase 1 Completed
37 enrolled 11 charts
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Phase 1/2 Completed
45 enrolled
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
Haplo Peripheral Blood Sct In GVHD Prevention
Phase 1 Completed
25 enrolled
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Phase 1 Completed
52 enrolled
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
PACIFICO
Phase 3 Completed
680 enrolled
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Phase 4 Completed
25 enrolled 17 charts
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Completed
29 enrolled
TIL
Phase 3 Completed
168 enrolled
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
GLYCAR
Phase 1 Completed
9 enrolled
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Phase 1 Completed
18 enrolled
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
Phase 2 Completed
22 enrolled 15 charts
GAIA
Phase 3 Completed
926 enrolled
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Phase NA Completed
44 enrolled 8 charts
TIL Therapy for Metastatic Renal Cell Carcinoma
Phase 1 Completed
5 enrolled 8 charts
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Phase 1 Completed
9 enrolled 16 charts
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Phase 2 Completed
7 enrolled 12 charts
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Phase 4 Completed
68 enrolled
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
Phase 3 Completed
230 enrolled
FluBuBe
Phase 2 Completed
50 enrolled
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Phase 1/2 Completed
49 enrolled 12 charts
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2 Completed
11 enrolled 12 charts
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
54 enrolled 18 charts
FluTBI
Phase 2 Completed
19 enrolled 15 charts
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Phase 1 Completed
19 enrolled
FLAT-Auto
Phase 2 Completed
15 enrolled
FluBuATG
Phase 1 Completed
20 enrolled
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Phase 2 Completed
20 enrolled 9 charts